Auf Lager:
1
Buch (Softcover): Fachbuch
Muromonab-CD3
Produkt bewerten
Verlag:
Betascript Publishing Unsere-Artikel-Nr.: 3225ZZK
EAN: 9786133024533
Auf Lager:
1
Zustellung: Do, 09.07.2026
Versand: Kostenlos
-17.2 %
CHF 169.–
CHF 140.–
Beschreibung
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans. Muromonab-CD3 was approved by the U. S. Food and Drug Administration (FDA) in 1986, making it the first monoclonal antibody to be used as a drug for humans worldwide. In the European Communities, it was the first drug to be approved under the directive 87/22/EWG, a precursor of the European Medicines Agency (EMEA) centralised approval system in the European Union. This process included an assessment by the Committee for Proprietary Medicinal Products (CPMP, now CHMP), and a subsequent approval by the national health agencies; in Germany, for example, in 1988 by the Paul Ehrlich Institute in Frankfurt.
Spezifikationen
Sprache
- Englisch
Autor
- Lambert M. Surhone
- Mariam T. Tennoe
- Susan F. Henssonow
Erscheinungsjahr
- 2010
Format
- Buch (Softcover)
Anzahl Seiten
- 76